VectivBio Seeks Slice Of Short Bowel Syndrome Market
As Offering Brings In $125m
The Switzerland-headquartered group believes it has a potentially best-in-class GLP-2 agonist on its hands with apraglutide, which has proved effective in a subgroup of patients that do not benefit from standard of care Gattex.
